Beneficial Effects of Incretin-Based Therapy on Glycemic Control, Adipokines, Insulin Sensitivity Parameters and Weight Loss in Overweight or Obese Patients With Newly Diagnosed Type 2 Diabetes: A Prospective Study

Abstract

Background: The aim of the study was to examine the incretin-based therapy on glycemic control, insulin sensitivity parameters, weight loss and adipokines in overweight or obese patients with newly diagnosed type 2 diabetes mellitus (T2DM).

Methods: This was a 24-week prospective study of 75 enrolled overweight or obese subjects (body mass index (BMI) is greater than or equal to 25 kg/m²) with newly diagnosed T2DM randomly assigned to the liraglutide, metformin, and sitagliptin groups. Outcome measures were fasting blood glucose (FBG), HbA1c, weight, BMI, waist circumstance, plasma lipids, fast insulin, fast C-peptide, HOMA-IR, HOMA-B, leptin, adiponectin, and high-sensitivity C-reactive protein (hsCRP).

Results: At the endpoint of 24 weeks, administration of liraglutide, metformin or sitagliptin all resulted in significant improvements of glycemic control, weight loss and insulin sensitivity parameters. It was also demonstrated that liraglutide was superior to metformin and sitagliptin in terms of achieving target HbA1c values and sustaining weight loss after 24-week treatment, but not to the incidence of adverse events (AEs). Moreover, liraglutide administration showed beneficial effects on reducing leptin levels and L/A ratio as well as elevating adiponectin levels compared to the metformin and sitagliptin administration.

Conclusion: Liraglutide treatment during 24 weeks in newly diagnosed T2DM patients led to reduction of BMI and improvement of glucose control, insulin sensitivity and resistance parameters. Additionally, circulating levels of adipokines could play an important role in GLP-1 treatment.




J Endocrinol Metab. 2015;5(5):284-290
doi: http://dx.doi.org/10.14740/jem304w